



Clinical Trial Plan Section	App.	Final	Pages
1. Document Purpose			9
2. Meetings & Contacts	Yes	Y	10
3. Legal Parties	Yes	Y	14
4. Investigator and Sponsor Study Administrative Structure			21
5. Trial Overview	Yes		27
5.1 Select Leading PI			30
5.2 Trial Management Planning			34
5.3 Assessment and Management of Risk			40
6. Rational for the Study			44
7. Competitive Products			46
8. Study Objectives			47
8.1 Primary			50
8.2 Secondary			51
8.3 Exploratory			52
8.4 Outcome measures/endpoints			53
8.4.1 Primary endpoint/outcome			62
8.4.2 Secondary endpoints/outcomes			64
9 Investigational Plan			65
9.1 Overall Study Design and Plan			68
9.2 Discussion of study design, including the choice of control group			78
9.3 Selection of study population			86
9.3.1 Number of Subjects			112
9.3.2 Inclusion Criteria			113



9.3.3 Exclusion Criteria			114
9.3.4 Removal of Subjects from Therapy or Assessments			117
9.4 Treatments			119
9.4.1 Treatments Administered			122
9.4.2 Identity of Investigational Product			125
9.4.3 Method for Assigning Subjects to Treatment Groups			127
9.4.4 Subject Numbering			129
9.4.5 Blinding			130
9.4.6 Selection of Doses in the Study (safety, PK, therapeutic effects)			136
9.4.7 Selection and timing of dose for each subject			139
9.4.8 Missed Doses			140
9.4.9 Excluded, prior and Concomitant medications			141
9.4.10 Treatment Compliance			143
9.5 Efficacy and Safety Assessment			145
9.5.1 Efficacy Assessments			147
9.5.2 Safety Assessments			148
9.5.3 Study Activities and Procedures by Study Visit			149
9.5.4. Study Extension			156
9.5.5 Appropriateness of Measurements			157
9.5.6 Primary Efficacy Variables			166
9.6 Study Drug Concentration measurements [if applicable]			167



9.7 Data Quality Assurance			168
9.8 Statistical Methods and Analytical Plans and Determination of Sample Size			169
9.8.1 Randomization			174
9.8.2 Analysis Population			184
9.8.3 Missing Data Group [if applicable]			186
9.8.4 Baseline and Demographic characteristics			195
9.8.5 Analysis of Primary Efficacy Variable			188
9.8.6 Secondary Analyses and Analysis of Secondary Efficacy Variable			190
9.8.7 Analysis of Safety Variables			191
9.8.8 Determination of Sample Size			192
9.8.9 Interim Analysis Methods [if applicable]			201
9.9 Protocol Development Standard			205
9.9.1 SPIRIT2013			210
9.9.2 MCC Protocol Scoring Standard			327
9.9.3 MCC Metrics			334
9.9.4 CTTI Quality by design in considering Clinical Trial			336
9.9.5 Study Feasibility Report			339
9.9.6 Protocol Feasibility Report and Questions checklist			353
10 Regulatory	Yes		354
11 Recruitment & Contingency Plan	Yes		369
12 Applicable SOPs	Yes		373
13 Work Scope, Task List, Study			376



黑卡会员（2 万元加入者） TM 身份专享

Deliverables and R&R			
14 Resources and Budgets	Yes		390
15 Vendor/Partner Management	Yes		424
16 Contract &Agreements			429
17 Performance Metrics & Reporting			431
18 Confidentiality of Data			435
19 Informed Consent			437
20 Investigational Product	Yes		446
21 Study Drug Accountability			448
22 Ethics			450
23 Protocol Adherence			461
24 Data Management	Yes		465
25 Electronic Case Report Forms			476
26 Retention of Records			480
27 Trial Documentation			485
28 <b>Safety Monitoring Guideline</b>	Yes		489
29 Adverse Events			498
29.1 Definitions			499
29.2 Evaluating and Recording Adverse Events			501
29.3 Reporting Adverse Events			502
30 Training			506
31 Investigator Meeting			507
32 Study Initiation			509
32.1 TRIAL SETTING			511
32.2 Principal Investigator (PI)/site selection			512
33 Study Execution			514
33.1 Addition of New Sites & Investigators			515



## 黑卡会员（2 万元加入者） TM 身份专享

33.2 Substantial amendment			516
33.3 Urgent Safety Measures			518
34 Study Monitoring	Yes		544
34.1 Trial Management			545
34.2 Progress Report			547
34.3 Ongoing Management & Monitoring			550
34.4 Audit			553
34.5 MHRA Inspection			554
35 Study Completion			556
36 Study Discontinuation			561
36.1 Trial Is abandoned			562
36.2 Early termination or temporary suspension of the trial			563
36.3 Temporary Halt or Early Termination			564
36.4 Trial does not Recommence			566
36.5 End of Trial Declaration			567
37 Preparation of Final Reports and Publication			569
37.1 Statistical Data Analysis			570
37.2 Trial results			572
37.3 Trial reports			574
37.4 Clinical Trial Summary Report			575
37.5 Reporting to participants			578
37.6 Publications			579
37.7 Dissemination of Results			580



黑卡会员（2 万元加入者） TM 身份专享

38 Archiving			584
38.1 Multisite trials: site documentation			587
38.2 Archiving data for further research			588
38.3 Electronic data			589
39 Preferences			584
40 Reference			587
41 APPENDICES			588